menu search

Intellia's (ntla) hae candidate gets ema's prime designation

The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA...

October 16, 2023, 2:17 pm

Intellia therapeutics receives priority medicines (prime) designation from the european medicines agency for ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioe

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focuse...

October 13, 2023, 12:38 pm

Intellia therapeutics receives priority medicines (prime) designation from the european medicines agency for ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioe

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focuse...

October 13, 2023, 12:38 pm

Pharvaris to present at the apaaaci 2023 international conference

ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor a...

October 13, 2023, 6:50 am

Oculis to present a late-breaking abstract at the 23rd euretina congress on positive phase 3 stage 1 diamond trial results for diabetic macular edema

ZUG, Switzerland, and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharm...

October 5, 2023, 6:30 am

Pharvaris to present at the ciic fall 2023 conference

ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor a...

October 4, 2023, 7:34 am

Pharvaris to participate in the 2023 cantor global healthcare conference

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...

September 19, 2023, 6:50 am

Biocryst pharmaceuticals rallies on quebec reimbursement for orladeyo angioedema treatment

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d'excellence en santé...

September 18, 2023, 10:53 am

Pharvaris to present at the 18th german allergy congress

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...

September 6, 2023, 6:51 am

Pharvaris to participate in the morgan stanley 21st annual global healthcare conference

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor ...

September 6, 2023, 6:50 am

Regeneron pharmaceuticals shares rise on fda approval of higher dose of eye disorder drug eylea

Regeneron Pharmaceuticals (NASDAQ:REGN) shares moved higher in pre-market trading after the biotechnology company reported on Friday that a higher dos...

August 21, 2023, 9:01 am

Regeneron shares climb after fda approval of macular degeneration treatment

Shares of Regeneron Pharmaceuticals Inc. REGN, +1.97% gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug A...

August 21, 2023, 7:52 am

Alti global, inc. (alti) q2 2023 earnings call transcript

AlTi Global, Inc. (NASDAQ:ALTI ) Q2 2023 Earnings Conference Call August 15, 2023 5:00 PM ET Company Participants Lily Arteaga - Head of Investor Rela...

August 19, 2023, 2:46 pm

Eylea hd (aflibercept) injection 8 mg approved by fda for treatment of wet age-related macular degeneration (wamd), diabetic macular edema (dme) and diabetic retinopathy (dr)

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Inje...

August 18, 2023, 10:35 pm

Nu holdings ltd. (nu) q2 2023 earnings call transcript

Nu Holdings Ltd. (NYSE:NU ) Q2 2023 Results Conference Call August 15, 2023 6:00 PM ET Company Participants Jorg Friedemann - IR Officer David Vélez ...

August 15, 2023, 11:40 pm

Aflibercept 8 mg two-year results from pivotal photon trial in diabetic macular edema presented at asrs

89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining thei...

July 29, 2023, 6:25 pm

Edema

Symptoms of edema include: Swelling or puffiness of the tissue right under the skin, especially in legs...

July 29, 2023, 12:29 pm

Kodiak (kod) down as late-stage dme studies fail

Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular ...

July 25, 2023, 10:53 am

Kodiak sciences discontinues development of eye disorder therapeutic; shares plummet

Kodiak Sciences shares fell by more than 45% after the biopharmaceutical company announced that it was discontinuing its tarcocimab program for eye di...

July 24, 2023, 1:59 pm

Astria (atxs) rises 5% on fast track tag for angioedema drug

Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to t...

July 21, 2023, 9:12 am


Search within

Pages Search Results: